, Tracking Stock Market Picks
Enter Symbol:
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

up 10.18 %

Regeneron Pharmaceuticals, Inc. (REGN) downgraded to Sell with price target $565 by UBS

Posted on: Wednesday,  Aug 5, 2015  11:25 AM ET by UBS

UBS rated Sell Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 08/05/2015, when the stock price was $592.80. Since
then, Regeneron Pharmaceuticals, Inc. has lost 9.24% as of 01/27/2016's recent price of $538.00.
If you would have followed this UBS's recommendation on REGN, you would have gained 10.18% of your investment in 175 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/5/2015 11:25 AM Sell
592.80 565.00
as of 8/27/2015
1 Week up  7.08 %
1 Month up  9.24 %
3 Months up  9.24 %
1 YTD up  9.24 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/11/2015 11:25 AM Hold
400.50 412.00
5/17/2013 10:25 AM Hold
267.42 290.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy